Eiger BioPharmaceuticals, Inc. Profile Avatar - Palmy Investing

Eiger BioPharmaceuticals, Inc.

Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is …

Biotechnology
US, Palo Alto [HQ]
US · Macroeconomic Factors/Risks · Forecasts

Macro

Eiger BioPharmaceuticals, Inc. mainly operates in US (Alpha-2: US, Alpha-3: USA)

United States
Analysis Results
B Overall Rating
19 Analyzed Indicators
B Annual Indicators Rating
16 Analyzed Indicators
B+ Monthly Indicators Rating
3 Analyzed Indicators
Breakdown

All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.

End of EIGR's Analysis
CIK: 1305253 CUSIP: 28249U105 ISIN: US28249U2042 LEI: - UEI: -
Secondary Listings
EIGR has no secondary listings inside our databases.